RNAZ
Transcode Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Transcode Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
No changes.
No changes.
No thesis.
—
Annual filing, covered
10-K parsed · Apr 15 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Apr 15 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
—
−27.37%
shares held · 6 largest managers
| Manager | Value | % base | |
|---|---|---|---|
| Yorkville Advisors Global | $121,958 | 58.62% | new |
| Vanguardindex-like | $40,644 | 19.53% | 0.00% |
| Vanguard Fiduciary Trustindex-like | $18,518 | 8.90% | 0.00% |
| UBS | $17,934 | 8.62% | −65.18% |
| FMR | $4,384 | 2.11% | new |
| Manager | Value | % base | |
|---|---|---|---|
| Yorkville Advisors Global | $121,958 | 58.62% | new |
| Vanguardindex-like | $40,644 | 19.53% | 0.00% |
| Vanguard Fiduciary Trustindex-like | $18,518 | 8.90% | 0.00% |
| UBS | $17,934 | 8.62% | −65.18% |
| FMR | $4,384 | 2.11% | new |
Transcode Therapeutics, Inc.
1.59
+0.02 · +1.06%
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNA–based agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9–based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNA–based agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9–based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.
—
—
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Transcode Therapeutics, Inc..
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Transcode Therapeutics, Inc..
Tall tick = annual report · Source: EDGAR
Largest filed tie
—
Expected move
No implied move.